Revance Therapeutics (RVNC) PT Raised to $54.00 at Mizuho
Revance Therapeutics (NASDAQ:RVNC) had its price target increased by stock analysts at Mizuho from $37.00 to $54.00 in a research report issued to clients and investors on Wednesday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Mizuho’s price target would indicate a potential upside of 55.40% from the company’s current price.
Other equities analysts also recently issued research reports about the company. Guggenheim started coverage on Revance Therapeutics in a research report on Tuesday. They issued a “buy” rating on the stock. Piper Jaffray Companies upped their price objective on Revance Therapeutics from $28.00 to $51.00 and gave the company an “overweight” rating in a research report on Tuesday. Cantor Fitzgerald set a $50.00 price target on Revance Therapeutics and gave the stock a “buy” rating in a research report on Tuesday. ValuEngine downgraded Revance Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday. Finally, Barclays initiated coverage on Revance Therapeutics in a research report on Monday, November 27th. They set an “overweight” rating and a $31.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $40.57.
Shares of Revance Therapeutics (NASDAQ:RVNC) opened at $34.75 on Wednesday. Revance Therapeutics has a twelve month low of $15.85 and a twelve month high of $37.20.
Revance Therapeutics (NASDAQ:RVNC) last issued its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.95) by ($0.06). Revance Therapeutics had a negative return on equity of 67.85% and a negative net margin of 37,161.00%. The firm had revenue of $0.08 million for the quarter, compared to analysts’ expectations of $0.05 million. During the same period last year, the company earned ($0.64) earnings per share. The firm’s revenue was up .0% on a year-over-year basis. equities research analysts anticipate that Revance Therapeutics will post -3.73 EPS for the current year.
In related news, CFO Lauren P. Silvernail sold 10,000 shares of Revance Therapeutics stock in a transaction that occurred on Tuesday, November 7th. The stock was sold at an average price of $26.83, for a total transaction of $268,300.00. Following the completion of the transaction, the chief financial officer now directly owns 59,006 shares in the company, valued at $1,583,130.98. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Mark J. Foley purchased 20,000 shares of Revance Therapeutics stock in a transaction that occurred on Tuesday, November 7th. The shares were bought at an average price of $26.96 per share, with a total value of $539,200.00. Following the completion of the transaction, the director now owns 6,000 shares of the company’s stock, valued at approximately $161,760. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 44,026 shares of company stock valued at $1,135,234. 18.86% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently modified their holdings of RVNC. SG Americas Securities LLC acquired a new stake in shares of Revance Therapeutics in the third quarter worth approximately $144,000. Legal & General Group Plc lifted its position in Revance Therapeutics by 8.1% during the second quarter. Legal & General Group Plc now owns 5,815 shares of the biopharmaceutical company’s stock worth $152,000 after buying an additional 438 shares in the last quarter. Bank of America Corp DE lifted its position in Revance Therapeutics by 29.5% during the first quarter. Bank of America Corp DE now owns 7,247 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 1,651 shares in the last quarter. Trexquant Investment LP purchased a new position in Revance Therapeutics during the second quarter worth approximately $231,000. Finally, Voya Investment Management LLC purchased a new position in Revance Therapeutics during the second quarter worth approximately $274,000. 88.70% of the stock is currently owned by institutional investors.
Revance Therapeutics Company Profile
Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.
Receive News & Ratings for Revance Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.